Sudhir Sivakumaran

Sudhir Sivakumaran, PhD, is Chief Scientific Officer of the Lewy Body Dementia Association, where he leads scientific strategy, translational research, and cross-sector partnerships to accelerate therapeutic development and improve outcomes for people living with Lewy body dementia. He brings more than two decades of experience across academia, biotechnology, pharmaceutical research, and nonprofit leadership, with expertise in translational neuroscience, biomarkers, clinical outcome assessments, regulatory science, and data-driven evidence generation. Previously, Dr. Sivakumaran served as Executive Director of the Critical Path for Alzheimer’s Disease consortium at the Critical Path Institute, leading global public-private collaborations among regulators, industry, academia, and patient organizations. He has also held scientific and leadership roles at Pfizer, Aptinyx, and Beacon Biosignals. His work focuses on moving patient organizations upstream in R&D so that patient and caregiver priorities inform development strategy, biomarker and endpoint selection, clinical trial design, trial readiness, and evidence planning from the outset. At LBDA, he is advancing initiatives in data aggregation, biomarker validation, meaningful outcome measurement, regulatory engagement, and industry partnership. He is a member of the Milken Institute’s 2026–2027 FasterCures LeadersLink cohort and holds a PhD in Neuroscience.

Please note that speakers provide their own biographies and headshots. Biographies represent the role of the person at the time of their engagement and are not independently verified by the Milken Institute.